Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 184Myelodysplastic Syndromes 82Leukemia 39Leukemia, Myelomonocytic, Chronic 36Recurrence 24Myeloproliferative Disorders 15Congenital Abnormalities 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Neoplasms 11Primary Myelofibrosis 9Melanoma 9Blast Crisis 9Thrombocythemia, Essential 7Polycythemia Vera 7Leukemia, Myelomonocytic, Acute 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Monocytic, Acute 7Hodgkin Disease 7Carcinoma, Non-Small-Cell Lung 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 6Anemia, Refractory, with Excess of Blasts 6Neoplasm Metastasis 5Lymphoma 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Biphenotypic, Acute 5Lymphoma, Non-Hodgkin 4Lung Neoplasms 4

Interventions

Cyclophosphamide 22blinatumomab 18Cytarabine 15fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Lenalidomide 7Dexamethasone 7Methotrexate 6Daunorubicin 6Mercaptopurine 5daratumumab 4Whole-Body Irradiation 4Vincristine 4Melphalan 4Idarubicin 4Etoposide 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Maintenance 3Immunotherapy, Adoptive 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Cladribine 3Asparaginase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × Decitabine × Clear all
NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Beijing 302 Hospital

Phase 2 Recruiting
67 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Beijing 302 Hospital

Phase 2 Unknown
52 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡